Nikolay Novitski/LinkedIn
May 5, 2026, 16:28
Nikolay Novitski: A New Era in Cardiovascular Prevention
Nikolay Novitski, Deputy chief physician, Associate professor Kaluga university, Board member Russian HF society, shared a post on X:
”Lipoprotein(a), or Lp(a), is an important cardiovascular risk factor that is largely unaffected by lifestyle changes or statin therapy.
Emerging therapies include:
- Pela (ASO) – approximately an 80 percent reduction (expected in 2026)
- Olpa (siRNA) – approximately a 71 to 101 percent reduction (expected in 2026)
- Lepo (siRNA) – approximately a 94 percent reduction, with effects lasting up to 1.5 years after a single injection
- Muva (oral) – approximately an 86 percent reduction in Lp(a)
Important note:
- Very low Lp(a) levels may be associated with an increased risk of type 2 diabetes.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 11:13Matteo Foschi: Grateful To Be Selected for The WSO Future Stroke Leaders Programme
-
May 12, 2026, 11:05Omid Seidizadeh: Strategies to Guide The 2nd 100 years of VWD Care and Research
-
May 12, 2026, 11:01Kate Scrivener: The Big Picture of Exercise Trials to Prevent Falls After Stroke
-
May 12, 2026, 10:39Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
-
May 12, 2026, 10:26Fabrice Cognasse: The EFS Is First and Foremost Part of a Medical Discipline – Transfusion
-
May 11, 2026, 16:52Luke McLaughlin: Raising Awareness on Haemophilia Issues at ENIL Lead On
-
May 11, 2026, 16:49Jeff Sternlicht: Normal LDL Does Not Always Mean Low Risk
-
May 11, 2026, 16:42Archil Jaliashvili: From Managing Blood to Managing Oxygen Metabolism
-
May 11, 2026, 16:42Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC